Baseline serum NTx levels are prognostic in metastatic breast cancer patients with bone-only metastasis
Authors:
- S. M. AliSAS. M. Ali
- L. M. DemersLDL. M. Demers
- K. LeitzelKLK. Leitzel
- H. A. HarveyHHH. A. Harvey
- D. ClemensDCD. Clemens
- N. MallinakNMN. Mallinak
- L. EngleLEL. Engle
- V. ChinchilliVCV. Chinchilli
- L. CostaLCL. Costa
- C. BradyCBC. Brady
- J. SeamanJSJ. Seaman
- A. LiptonALA. Lipton
Open Access
- 1 March 2004
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 15 (3) , 455-459
Abstract
Background: There is significant heterogeneity in survival of patients with metastatic breast cancer who have bone-only metastasis. We studied the correlation of serum N-telopeptide (NTx), a marker of bone resorption, and its correlation with clinical outcomes in patients with metastatic breast cancer with bone-only or bone plus soft tissue metastasis. Patients and methods: Serum was taken from 250 metastatic breast cancer patients with bone-only or bone plus soft tissue metastasis who participated in two similar randomized studies of second-line hormone therapy. An enzyme-linked immunosorbent assay specific for NTx of type I bone collagen was used to detect serum levels. Results: Sixty patients (24%) had elevated serum NTx levels, using the mean + 2 standard deviations (26 nanomoles Bone Collagen Equivalents per liter) of healthy women as a cut-off. The median duration of clinical benefit was significantly shorter in the group with elevated serum NTx levels compared with the group that had normal serum NTx levels (P = 0.0004). Time to progression (TTP) was also significantly shorter in the patients with elevated serum NTx at 139 days compared with 220 days (P = 0.0006). Median survival was also significantly shorter in patients with elevated baseline serum NTx levels at 663 days compared with 941 days (P Conclusion: In this study, breast cancer patients with bone-only or bone plus soft tissue metastasis and elevated serum NTx levels have a shorter duration of clinical benefit, TTP and overall survival.Keywords
This publication has 15 references indexed in Scilit:
- Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer GroupJournal of Clinical Oncology, 2001
- Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741Journal of Clinical Oncology, 1999
- Clinical course and prognostic factors following bone recurrence from breast cancerBritish Journal of Cancer, 1998
- Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer.Journal of Clinical Oncology, 1997
- Molecular Site Specificity of Pyridinoline and Pyrrole Cross-links in Type I Collagen of Human BoneJournal of Biological Chemistry, 1996
- Fadrozole HCL (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: Results of two randomized double blind controlled multiinstitutional trialsCancer, 1996
- A specific immunoassay for monitoring human bone resorption: Quantitation of type I collagen cross-linked N-telopeptides in urineJournal of Bone and Mineral Research, 1992
- Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.Journal of Clinical Oncology, 1991
- Comprehensive management of disseminated breast cancerCancer, 1990
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987